Last reviewed · How we verify
Margetuximab Margetuximab-IV
At a glance
| Generic name | Margetuximab Margetuximab-IV |
|---|---|
| Sponsor | Zai Lab (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MARGetuximab Or Trastuzumab (MARGOT) (PHASE2)
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (PHASE2, PHASE3)
- Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (PHASE3)
- Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer (PHASE1, PHASE2)
- A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC (PHASE2)
- A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Margetuximab Margetuximab-IV CI brief — competitive landscape report
- Margetuximab Margetuximab-IV updates RSS · CI watch RSS
- Zai Lab (Shanghai) Co., Ltd. portfolio CI